- Home
- ILMN vs FWONK Comparison
ILMN vs FWONK Comparison
Compare ILMN & FWONK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILMN
- FWONK
- Stock Information
- Founded
- ILMN 1998
- FWONK 1950
- Country
- ILMN United States
- FWONK United States
- Employees
- ILMN N/A
- FWONK N/A
- Industry
- ILMN Medical Specialities
- FWONK Broadcasting
- Sector
- ILMN Health Care
- FWONK Industrials
- Exchange
- ILMN Nasdaq
- FWONK Nasdaq
- Market Cap
- ILMN 23.6B
- FWONK 23.6B
- IPO Year
- ILMN 2000
- FWONK N/A
- Fundamental
- Price
- ILMN $136.67
- FWONK $91.20
- Analyst Decision
- ILMN Buy
- FWONK Buy
- Analyst Count
- ILMN 17
- FWONK 4
- Target Price
- ILMN $162.76
- FWONK $102.33
- AVG Volume (30 Days)
- ILMN 2.1M
- FWONK 1.1M
- Earning Date
- ILMN 02-06-2025
- FWONK 02-26-2025
- Dividend Yield
- ILMN N/A
- FWONK N/A
- EPS Growth
- ILMN N/A
- FWONK N/A
- EPS
- ILMN N/A
- FWONK 1.15
- Revenue
- ILMN $4,390,000,000.00
- FWONK $3,716,000,000.00
- Revenue This Year
- ILMN N/A
- FWONK $20.86
- Revenue Next Year
- ILMN $4.08
- FWONK $10.14
- P/E Ratio
- ILMN N/A
- FWONK $79.04
- Revenue Growth
- ILMN N/A
- FWONK 35.32
- 52 Week Low
- ILMN $97.36
- FWONK $62.56
- 52 Week High
- ILMN $156.66
- FWONK $96.90
- Technical
- Relative Strength Index (RSI)
- ILMN 47.37
- FWONK 48.42
- Support Level
- ILMN $131.75
- FWONK $89.77
- Resistance Level
- ILMN $153.06
- FWONK $94.41
- Average True Range (ATR)
- ILMN 5.42
- FWONK 2.02
- MACD
- ILMN 0.29
- FWONK -0.59
- Stochastic Oscillator
- ILMN 28.30
- FWONK 25.77
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
About FWONK Liberty Media Corporation Series C Liberty Formula One
Formula One Group controls the exclusive commercial and promotional rights to the FIA Formula One World Championship series, and the monetization of those rights is the primary business of the group. The firm is responsible for development and promotion of the Formula One race series in concert with its three partners: the FIA (the regulatory body), the teams that participate in the series, and the series' commercial partners, which include the race promoters, broadcasters, sponsors, and advertisers. The F1 schedule in 2023 will encompass 23 races held on five continents. Formula One Group is a subsidiary of Liberty Media, which purchased the firm in January 2017. Formula One stock is a tracking stock for the assets under Formula One Group with Liberty Media.